Skin Cancer

Long-Term Survival With Dabrafenib Plus Trametinib in Metastatic BRAF-Mutated Melanoma

In an extended analysis of the COMBI-d and COMBI-v trials reported at the 2019 ASCO Annual Meeting and in The New England Journal of Medicine...

Issues in Oncology
Cost of Care

Major Settlement Raises Questions About Evidence-Based Value in Cancer Care

An Oklahoma jury recently awarded $25.5 million to the widower of a 53-year-old woman diagnosed with stage IV nasopharyngeal cancer who was denied coverage...

Breast Cancer

New TAILORx Data Provide Treatment Guidance for Women Under 50 With Early Breast Cancer

New information about adjuvant therapy to prevent recurrence of breast cancer in women 50 years of age or younger has emerged from...


Addition of a Tyrosine Kinase Inhibitor to Immunotherapy in Advanced Sarcomas

In a phase II trial reported in The Lancet OncologyBreelyn Wilky, MD, and colleagues found evidence of activity of axitinib plus pembrolizumab in advanced sarcomas...

Lung Cancer

Addition of Bevacizumab to Erlotinib Improves Progression-Free Survival in EGFR-Mutated, Nonsquamous NSCLC

In an interim analysis of the phase III NEJ026 trial reported in The Lancet OncologyMakoto Maemondo, MD, and colleagues found that the addition of bevacizumab...


More Top Stories

Multiple Myeloma
Issues in Oncology

Kamal Chamoun, MD, on Multiple Myeloma: Insurance Status and Survival

Breast Cancer

Nipple-Sparing Mastectomy May Be Suitable for Growing Number of Well-Selected Patients

As nipple-sparing mastectomy gains favor, it is being performed on a broader spectrum of patients once considered off limits by surgeons. A Mayo Clinic study in a contemporary cohort found no increase in complication rates or decrease in reconstruction success with this surgical approach.1...


2019 ASCO: Paclitaxel/Carboplatin vs Paclitaxel/Ifosfamide in Carcinosarcoma of the Uterus or Ovary

Results from the phase III NRG Oncology clinical trial GOG 0261 comparing paclitaxel plus carboplatin to paclitaxel plus ifosfamide in women with stage I–IV recurrent carcinosarcoma of the uterus or ovary found that treatment with paclitaxel/carboplatin was not inferior to...

Solid Tumors

Sarah Abou Alaiwi, MD, and Toni K. Choueiri, MD, on Checkpoint Inhibitors: Overall Survival and Polybromo-Associated Mutations

Hematologic Malignancies

Ibrutinib in Combination With Obinutuzumab in Treatment-Naive CLL/SLL

In the Clinic provides overviews of novel hematology and oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Early in 2019, ibrutinib was approved for ...

New: ASCO Answers Fact Sheet on Fertility and Cancer Treatment for Your Patients

Cancer and cancer treatment can cause infertility in both men and women. Prepare your patients for this possibility by giving them the ASCO Answers fact sheet titled Your Fertility and Cancer Treatment. This fact sheet covers: An overview of what fertility and infertility mean Which cancer...

2019 ASCO: OPTiM Study on T-VEC for Unresectable Melanoma

New research on the immunotherapy talimogene laherparepvec (T-VEC)—an injectable oncolytic virus—for patients with unresectable melanoma was presented by Milhem et al at the 2019 ASCO Annual Meeting (Abstract 9524). Researchers reported the ad hoc analysis of progression-free survival...

Breast Cancer

Sara A. Hurvitz, MD, on HR+/HER2− Advanced Breast Cancer: MONALEESA-7 Trial on Endocrine Therapy With or Without Ribociclib

Engage With CENTRA: ASCO’s Center for Research and Analytics

In 2017, ASCO announced the launch of its Center for Research and Analytics (CENTRA). CENTRA’s mission is to conquer cancer by generating, integrating, analyzing, and sharing oncology data to foster innovation in research and patient care. CENTRA aims to make its cancer data available to the...


2019 ASCO: Long-Term Survival With Dabrafenib Plus Trametinib in Metastatic BRAF-Mutated Melanoma

In an extended analysis of the COMBI-d and COMBI-v trials reported at the 2019 ASCO Annual Meeting (Abstract 9507) and in The New England Journal of Medicine, Robert et al found a 5-year overall survival rate of 34% with the combination of dabrafenib and trametinib in previously untreated...